NRX Pharmaceuticals (NRXP) EBT (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly EBT of -$5.0 million for Q1 2026, down 29.33% year-over-year from -$7.0 million in Q1 2025, and down 1.08% quarter-over-quarter from -$4.9 million in Q4 2025.
NRX Pharmaceuticals (NRXP) EBT (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported EBT for 10 consecutive years, with -$5.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 29.33% year-over-year to -$5.0 million; the TTM figure through Mar 2026 stood at -$17.8 million (down 10.13% YoY), while the FY2025 annual figure was -$67.4 million, up 1.04% from the prior year.
- EBT fell to -$5.0 million in Q1 2026 per NRXP's latest filing, from -$4.9 million in the prior quarter.
- Across five years, EBT topped out at -$2.3 million in Q4 2024 and bottomed at -$16.7 million in Q1 2022.
- Historically, EBT has averaged -$6.5 million across 5 years, with a median of -$5.0 million in 2026.
- Annual changes were most pronounced in 2022 — EBT plunged 8190.75% — and 2023, when it surged 76.26%.
- NRX Pharmaceuticals' EBT stood at -$12.3 million in 2022, then soared by 63.3% to -$4.5 million in 2023, then soared by 49.44% to -$2.3 million in 2024, then tumbled by 115.28% to -$4.9 million in 2025, then decreased by 1.08% to -$5.0 million in 2026.
- Business Quant data shows NRXP's EBT at -$5.0 million in Q1 2026, -$4.9 million in Q4 2025, and -$4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -6.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.97 Mn |
| Dec 31, 2025 | -4.92 Mn |
| Sep 30, 2025 | -4.21 Mn |
| Jun 30, 2025 | -3.73 Mn |
| Mar 31, 2025 | -3.84 Mn |
| Dec 31, 2024 | -2.28 Mn |
| Sep 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -7.04 Mn |
| Mar 31, 2024 | -6.35 Mn |
| Dec 31, 2023 | -4.52 Mn |
| Sep 30, 2023 | -6.19 Mn |
| Jun 30, 2023 | -8.09 Mn |
| Mar 31, 2023 | -3.97 Mn |
| Dec 31, 2022 | -12.31 Mn |
| Sep 30, 2022 | -9.32 Mn |
| Jun 30, 2022 | -9.75 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -30.41 Mn |
| Sep 30, 2021 | -37.05 Mn |
| Jun 30, 2021 | -117,613.00 |